obesity drug news today glp-1 september 29 2025 There's lots going on this month at FDA in the world of weight loss drugs. The agency is taking a hard look at the market. Check out these new #FDA Warning Letters A network meta-analysis backed weight-loss

Semaglutide, liraglutide, and dulaglutide have all demonstrated modest systolic blood pressure reductions in clinical studies

N.GriloC

Patients in Dubai and Abu Dhabi can access these options after a consultation with our endocrinologist, with the standard support: free medication delivery (no markup), monthly follow-ups, body-composition tracking on every visit, and ongoing lifestyle coaching

"We're really pushing hard to get into that second position behind orforglipron, now Foundayo." Pfizer also unveiled mid-stage data from a shot it gained through its $10 billion acquisition of Metsera

The glucagon receptor activation drives this effect by promoting hepatic fat oxidation, essentially telling the liver to burn its stored fat reserves